The advent of the adrenal corticosteroids a few years ago marked a new era in ocular therapeutics. Before the values of cortisone had been finally assessed by researchers, this hormone was somewhat overshadowed by the introduction of its more potent relative, hydrocortisone. The brief passage of time has not allowed complete clarification of their roles in ophthalmology; however, certain facts have become well established. The value of adrenal steroids as potent therapeutic agents in ocular inflammation and allergic states is accepted. The indications, contraindications, dosages, routes of administration, and principal physiologic effects have been well outlined by many authors from clinical and experimental studies.
The horizon of this new era of adrenal steroids has been extended by the recent synthesis of two more potent and less toxic corticosteroids, prednisone * (Meticorten) and prednisolone † (Meticortelone). It is the purpose of this preliminary report to introduce these new substances to the field
KING JH, WEIMER JR. Prednisone (Meticorten) and Prednisolone (Meticortelone) in Ophthalmology: Experimental and Clinical Studies. AMA Arch Ophthalmol. 1955;54(1):46–54. doi:10.1001/archopht.1955.00930020048007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.